E-Cigarette Infographic

| November 8, 2018

article image
With this infographic, you can see facts about the electronic cigarette. We illustrate how the different parts of an electronic cigarette work together, how many of the total world population that uses electronic cigarettes and then you can see a comparison of electronic cigarettes versus traditional cigarettes.

Spotlight

Rational Vaccines

Rational Vaccines (RVx) was formed in 2015 for the purpose of offering better solutions to stop the spread of herpes and alleviate the problems faced by people suffering with unrelenting, chronic disease. Based on the life work of Dr. Bill Halford, Associate Professor, Southern Illinois University Medical School, who studied herpes simplex virus 1 and 2 (HSV-1 and HSV-2) in a laboratory setting for 25 years, RVx has developed the world’s first line of rationally-engineered live HSV-1 and HSV-2 vaccines that have been shown across 10 years of pre-clinical studies to be safe and highly immunogenic. RVx has also developed a novel type-specific diagnostic method, the ABVIC test, for serological testing of patients for HSV-1 and/or HSV-2 infection, which greatly improves upon the existing standard of care. Through the development of rationally-engineered live viral vaccines and a more accurate and reliable HSV diagnostic test, RVx is forging the path ahead to a brighter future.

OTHER ARTICLES

New Dimensions of Clinical Trial Optimization

Article | April 20, 2021

For much of the past three decades, even as methodologies for clinical trial design have advanced and refined, the idea of the optimized clinical trial has centered on optimal patient samples, target enrollment rates, and generally the most efficient uses of scarce resources in the form of patients. Yet anyone who has had to design and optimize a clinical trial, knows that trial optimization occurs within an ecosystem of choices; a series of choices that stretch from the time it takes to implement a clinical trial and submit clinical data for analysis, to general concerns about the cost and power of a clinical trial. A true clinical trial optimization process would try to unify a number of these choices into a single framework for trial optimization. The complexity of clinical trial optimization comes from the need to align priorities on the one hand, and to understand opportunities on the other. We know that at a very general level, clinical operations specialists benefit from simplicity in clinical trial design, and that commercial teams prefer shorter clinical trials to longer ones. We also know that the statistical design of a clinical trial can influence both simplicity and duration. Yet how many sponsors have their clinical operations and commercial teams, sit with their R&D teams to review various statistically nuanced design options? For many sponsors, the reason this process does not occur as often as it should, is because the nuanced statistical parameters of a clinical trial design are very difficult to communicate to non-statisticians. Yet a trial optimization tool like Solara, equipped with data visualizations and the ability to see tradeoffs intuitively, can overcome this challenge. The real challenge is often convincing the non-statistician that they have a stake in clinical trial design. Cytel recently had a client that thought it needed a sample size re-estimation design, because it had a very strict limit on the number of patients it could enroll. After a few hours of working with Solara, though, a statistician discovered that a much simpler Group Sequential Design would deliver comparable power using about the same number of patients. The gains from the more complex design were minimal from the optimization perspective, when understood as the eco-system of choices. Similarly, most commercial teams pressure their clinical trial designers to have the most accelerated clinical trial imaginable, but as we all know, the longer the clinical trial the more likely there will be a higher number of events that demonstrate the effectiveness of a new medicine. So commercialization teams have a stake in longer clinical trials, even when their rule of thumb is to shorten them. Therefore, it is absolutely essential to communicate the benefits of various statistical designs to multiple stakeholders in a way that makes tradeoffs clear. Aligning on priorities early during the clinical trial design process is essential to selecting the optimal clinical trial. Yet for this statisticians need to be equipped for both a strategic and communicative role in the R&D process.

Read More

The Future of Pharma Beyond Blockbusters

Article | March 17, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 4, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

How pharma can continue engaging HCPs in a world gripped by COVID-19

Article | April 10, 2020

Medscape is the leading source of clinical news, health information, and point-of-care tools for healthcare professionals. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools. Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses and other educational programmes for physicians, nurses, and other healthcare professionals. Both Medscape and Medscape Education are part of WebMD Health Corp., an Internet Brands company. Face-to-face interactions between pharma and physicians have essentially ceased overnight during the COVID-19 pandemic, but that doesn’t mean HCPs have stopped looking for new medical information.

Read More

Spotlight

Rational Vaccines

Rational Vaccines (RVx) was formed in 2015 for the purpose of offering better solutions to stop the spread of herpes and alleviate the problems faced by people suffering with unrelenting, chronic disease. Based on the life work of Dr. Bill Halford, Associate Professor, Southern Illinois University Medical School, who studied herpes simplex virus 1 and 2 (HSV-1 and HSV-2) in a laboratory setting for 25 years, RVx has developed the world’s first line of rationally-engineered live HSV-1 and HSV-2 vaccines that have been shown across 10 years of pre-clinical studies to be safe and highly immunogenic. RVx has also developed a novel type-specific diagnostic method, the ABVIC test, for serological testing of patients for HSV-1 and/or HSV-2 infection, which greatly improves upon the existing standard of care. Through the development of rationally-engineered live viral vaccines and a more accurate and reliable HSV diagnostic test, RVx is forging the path ahead to a brighter future.

Events